EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current state and advances in desensitization for peanut allergy in pediatric age

Simone Foti Randazzese iD, Ilenia Panasiti iD, Lucia Caminiti, Francesco Catamerò iD, Massimo Landi, Maria De Filippo, Martina Votto, Roberta Olcese, Filippo Favuzza, Mattia Giovannini iD, Salvatore Barberi

Pediatric Allergy and Immunology · 2024

DOI: 10.1111/pai.14127 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Allergy and Immunology, 2024. Verfasst von Simone Foti Randazzese und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Desensitization, Immunologic, Allergens. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peanut allergy affects about 1%–3% of the pediatric population in the world, with an important increase in the last decades. Nowadays, international guidelines recommend the early introduction of peanuts in the infant diet, with poor information about the quantity and the frequency of the intake. Allergen immunotherapy may represent the only therapeutic strategy able to modify the natural history of peanut allergy. In particular, oral immunotherapy showed the most promising results in terms of efficacy, but with significant rates of adverse reactions, mostly gastrointestinal. In 2020, the Food and Drug Administration and the European Medicines Agency approved Palforzia®, an oral drug for patients aged 4–17 years. Several studies are ongoing to improve the tolerability of oral immunotherapy and standardize the desensitization protocols. Sublingual immunotherapy permits to offer much lower doses than oral immunotherapy, but fewer adverse events are shown. Subcutaneous immunotherapy is associated with the greatest systemic adverse effects. Epicutaneous immunotherapy, for which Viaskin® patch was approved, has the highest safety profile. Innovative studies are evaluating the use of biological drugs, such as omalizumab or dupilumab, and probiotics, such as Lactobacillus rhamnosus , in monotherapy or associated with oral immunotherapy. Therapy for peanut allergy is constantly evolving, and new perspectives are ongoing to develop. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peanut HypersensitivityDesensitization, ImmunologicAllergensHumansChildChild, PreschoolAdolescentAdministration, OralArachisProbiotics

Stichwörter der Autor:innen

allergen immunotherapyallergychildrendesensitizationpeanut

Substanzen

Allergens

Autor:innen und Institutionen

  • Pediatric Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.
  • Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Department of Health Sciences, University of Florence, Florence, Italy.
  • Institute of Biomedicine and Molecular Immunology, Pediatric National Healthcare System, Turin, Italy.
  • Pediatric Unit, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

ORCID-Profile: Simone Foti Randazzese, Ilenia Panasiti, Francesco Catamerò, Mattia Giovannini

Zitieren

APA

Foti Randazzese, S., Panasiti, I., Caminiti, L., Catamerò, F., Landi, M., De Filippo, M., Votto, M., Olcese, R., Favuzza, F., Giovannini, M., & Barberi, S. (2024). Current state and advances in desensitization for peanut allergy in pediatric age. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.14127

Vancouver

Foti Randazzese S, Panasiti I, Caminiti L, Catamerò F, Landi M, De Filippo M, et al. Current state and advances in desensitization for peanut allergy in pediatric age. Pediatric Allergy and Immunology. 2024. doi:10.1111/pai.14127

BibTeX
@article{FotiRandazzese2024,
  author = {Foti Randazzese, Simone and Panasiti, Ilenia and Caminiti, Lucia and Catamerò, Francesco and Landi, Massimo and De Filippo, Maria and Votto, Martina and Olcese, Roberta and Favuzza, Filippo and Giovannini, Mattia and Barberi, Salvatore},
  title = {Current state and advances in desensitization for peanut allergy in pediatric age},
  journal = {Pediatric Allergy and Immunology},
  year = {2024},
  doi = {10.1111/pai.14127}
}
Kostenlos starten →